September 24,
2010Dear
Colleagues,
UNAIDS and AVAC invite
stakeholders in biomedical HIV prevention
research to join a webinar on
the
draft second edition of the Good Participatory
Practice (GPP) Guidelines for biomedical HIV
prevention trials on Tuesday, 05 October
from 9am – 10am US Eastern Time / 3pm - 4pm
Geneva time. (For other time zones, please
visit
www.timeanddate.com.)
Click
here to register for the call.
The objectives of
the webinar are to:- Orient
stakeholders to the second edition of the GPP
guidelines.
- Provide an opportunity for
discussion and questions around GPP issues and
the second edition.
- Encourage
stakeholders to review the guidelines and send
comments on the draft second edition by 31
October.
Webinar details:The GPP guidelines were first
published in 2007. Following consultation with
various stakeholders, the guidelines were
revised and a second edition was released as a
draft at the International AIDS Conference in
Vienna in July. This draft is open for public
comment until 31 October 2010. The final
version of the second edition of the guidelines
will be released in late 2010.
The GPP
guidelines were created to set global standards
for stakeholder engagement in biomedical HIV
prevention trials. The GPP guidelines are
intended to provide trial funders, sponsors and
implementers with systematic guidance on how to
effectively engage with all stakeholders in the
design and conduct of biomedical HIV prevention
trials. Community members and others can also
use the GPP guidelines to evaluate engagement
efforts by trial funders, sponsors and
implementers. The GPP guidelines are the first
set of global guidelines that address community
engagement in biomedical HIV prevention
trials.
The second edition of the GPP Guidelines
consists of three
sections:- Complexities of
Biomedical HIV Prevention Trials
describes the realities of the HIV
epidemic, the underlying determinants of the
epidemic, the context of conducting biomedical
HIV prevention trials, and why a participatory
approach is necessary to effectively conduct
trials.
- Guiding Principles of GPP in Biomedical
HIV Prevention trials outlines the set
of principles that serve as the foundation of
the relationship between trial funders,
sponsors, implementers, and other stakeholders.
These include Respect, Mutual Understanding,
Scientific and Ethical Integrity, Transparency,
Accountability, and Community
Autonomy.
- Standards of Good Participatory Practice
in Biomedical HIV Prevention Trials
describes standards of good
participatory practice for trial funders,
sponsors, and implementers to follow when
designing, preparing for, conducting, and
concluding a biomedical HIV prevention trial.
This section discusses stakeholder engagement
activities to take place at each stage of the
research life-cycle. Examples of stages covered
in the GPP standards section are Formative
Research Activities, Stakeholder Advisory
Mechanisms, Community Education Plan, Protocol
Development, Standard of HIV Prevention, Access
to HIV Care and Treatment and Trial Closure and
Results Dissemination.
Download
the draft second edition of GPP for public
comment.
We look forward to
discussing the GPP guidelines with you on 05
October. Please
register
for the call here. (The call will be
recorded and available on the GPP page of the
AVAC website:
www.avac.org/gpp for those
of you unable to join the
call.)
If you have any questions,
please don't hesitate to
email us.
Comments on the GPP guidelines can be emailed
to
avac@avac.org or
gpp@unaids.org.
Best,
UNAIDS and
AVAC
